Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trial
read at Endpoints ↗DealPositive
Kallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine.
The rebrand follows a recent partnership with Novo on an obesity program, and the company secured $94 million to fund Phase 3 trials of a migraine candidate originally discovered by Tanabe Pharma.
The new capital will support the Phase 3 study and the company's exclusive focus on migraine therapeutics under the TriGemX Bio brand.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug”
read at Endpoints ↗98 words · retrieved 42m ago
comments(0)
5-min edit window · permanent after that